Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3CNS 3Thoracic 2Sarcoma 2Head & Neck 2Endocrine 2Breast 2Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Thyroid Cancer, Papillary 3Colonic Neoplasms 3Carcinoma, Medullary 3Thyroid Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms by Site 2Neoplasms 2Lung Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Sarcoma 1Pancreatic Neoplasms 1Myofibromatosis 1Gastrointestinal Neoplasms 1

Interventions

selpercatinib 2Trastuzumab 2Paclitaxel 2sodium thiosulfate 1pazopanib 1glutathione pegylated liposomal doxorubicin 1fluoroacetic acid 1elacestrant 1durvalumab 1carboxyamido-triazole 1abemaciclib 1Temozolomide 1Taxes 1Surveys and Questionnaires 1RAD1901 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Methotrexate 1Magnetic Resonance Spectroscopy 1MLN 8237 1Levofloxacin 1Lapatinib 1Immunotherapy 1Immunoenzyme Techniques 1Genetic Testing 1Genetic Counseling 1Gemcitabine 1Drug Therapy 1D-methadone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × selpercatinib × Breast × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡